Controllare lo stato dell'ordine

Entra a far parte di una comunità di amanti dei libri di tutto il mondo e ottieni numerosi vantaggi. Crea un account gratuito

Punto Poste 5.49 € Punto Poste 5.49 € Corriere DHL 6.99 € Corriere GLS 5.99 € Punto GLS 4.49 € Corriere Bartolini 4.49 € Punto Bartolini 3.49 €

Contatto

Come acquistare

Aiuto

Il mio account

▸ Vuoto :-(

Drugs for HER-2-positive Breast Cancer

Name: Drugs for HER-2-positive Breast Cancer
Brand: Birkhauser Verlag AG
SKU: 01438610
Price: 160.79 EUR
Availability: InStock
Author: Maria Sibilia
ISBN: 9783034600934

Maria Sibilia

Christoph C. Zielinski

Rupert Bartsch

Lingua

Inglese

Libro Rigido

Codice Libristo: 01438610

Casa editrice Birkhauser Verlag AG, gennaio 2011

Growth factor receptors have long been known to drive malignant transformation and cancer progressio... Descrizione completa

Codice Libristo: 01438610

393 b

160.79 €

Magazzino esterno Inviamo tra 10-13 giorni

Fino a 30 giorni per il reso

I clienti hanno acquistato anche

«Tu che personaggio fai?» Il burattino fra realtà e fantasia Nadia Fumini

Libro

25.80 €

Hormonálna inteligencia Aviva Romm

Rigido

33.59 €

Badische Kuche Komet verlag

Adobe ePub DRM

4.59 €

Na posterunku. Udział polskiej policji granatowej i kryminalnej w Zagładzie Żydów wyd. 2 Jan Grabowski

In brossura

7.99 €

Catherine Deneuve, reflets Marc-Antoine Coulon

In brossura

43.51 €

La marquesa de La Habana Eduardo Quiles

In brossura

4.69 €

Seligmann Alexandre Ou Les Tribulations d'Un Israelite Strasbourgeois Pendant La Terreur Reuss-R

In brossura

13.00 €

Mizmiz Mirnav 4; Pastel Boya Ayla cinaroglu

In brossura

15.00 €

Lebens[Ge]dichte Fritz Herzog

In brossura

10.49 €

Traite Des Impots Tome 2 Marie-Louis-Pierre Felix Esquirou Parieu (De)

In brossura

29.09 €

Bedrohte Und Ausgerottete Tiere Vinzenz Ziswiler

In brossura

50.29 €

drei Zeittanzerinnen Peter Rupprecht

In brossura

7.69 €

Kaiser Augustus und seine Zeit im Spiegel horazischer Dichtung Christian Kneer

In brossura

12.49 €

Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting.